Presentation Materials
The Latest Presentation Materials
Products / R&D
Information Meeting on Rozlytrek®
Date:
September 05, 2019
Presentations:
- Product Overview of Rozlytrek®
- Yoshito Nakanishi,
Rozlytrek® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd. - From organ specific to gene specific cancer treatment
- Expectations on ROZLYTREK for NTRK Fusion-Positive Solid Tumors - - Takayuki Yoshino, MD, PhD
Director, Department of Gastroenterology and Gastrointestinal Oncology,
National Cancer Center Hospital East (NCCE), Japan
Co-principal investigator, GI-SCREEN-Japan
Materials:
Select a category
2019
-
Sep 03,2019
- Chugai CEO Meeting
-
Corporate
Tatsuro Kosaka, President and CEO
Yasushi Ito, Executive Vice President, Co-Head of Project & Lifecycle Management Unit
-
Jul 26,2019
- Investor Conference on FY2019 2Q Financial Results
-
Results
- Aiming to Achieve the Mid-term Business Plan “IBI 21”
- FY2019 Half Year Results - - Tatsuro Kosaka,
President and CEO - FY2019 2Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
- Aiming to Achieve the Mid-term Business Plan “IBI 21”
-
Jul 04,2019
- Information Meeting on FoudationOne® CDx
-
Products / R&D
- 1. FoundationOne® CDx Cancer Genomic Profile Product Overview
- Kosuke Iijima, Department Manager of Foundation Medicine Business Dept., Foundation Medicine Unit
- 2. Cancer Genomic Medicine
- Clinical Implementation and Challenges - - Prof. Muto Manabu, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University
-
Jun 18,2019
- ESG Meeting
-
Corporate
Motoo Ueno, Representative Director, Deputy Chairman
-
Apr 24,2019
- 1Q Results (Jan - Mar 2019) Conference Call
-
Results
Products / R&D
- FY2019 1Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President & CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
-
Feb 01,2019
- Investor conference on FY 2018.12 Financial Results
-
Results
- New Mid-term Business Plan “IBI 21”
- Tatsuro Kosaka,
President and CEO - FY2018 Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
2018
-
Nov 07,2018
- Information Meeting on GAZYVA®
-
Products / R&D
- 1. Product Overview of GAZYVA® Intravenous Infusion 1000 mg
- Naoko Oya, GAZYVA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. Pathology of Follicular Lymphoma and Clinical Trial Results of obinutuzumab
- Kiyohiko Hatake, M.D., Ph.D.
Deputy Director, Head of the Malignant Tumor and Hematologic Tumor Center at the International University of Health and Welfare, Mita Hospital, Japan
-
Oct 24,2018
- 3Q Results (Jan - Sep 2018) Conference Call
-
Results
Products / R&D
- FY2018 3Q Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President & CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
-
Aug 28,2018
- Chugai CEO Meeting
-
Corporate
Tatsuro Kosaka, President and CEO
-
Jul 27,2018
- Investor Conference on FY2018 2Q Financial Results
-
Results
Products / R&D
- Aiming to Achieve Mid-term Business Plan “IBI 18”
- FY2018 Half Year Results - - Tatsuro Kosaka,
President and CEO - FY2018 2Q Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
- Presentation [PDF 1.0MB]
- Webcast(END)
- Aiming to Achieve Mid-term Business Plan “IBI 18”
-
Jun 01,2018
- Information Meeting on HEMLIBRA®
-
Products / R&D
- 1. HEMLIBRA® Subcutaneous Injection Product Overview
- Hiroshi Motegi, HEMLIBRA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. Current Status of Hemophilia Treatment and Expectations for HEMLIBRA®
- Prof. Midori Shima, M.D., Ph.D.
Department of Pediatrics, Nara Medical University
- Presentation [PDF 3.3MB]
- Webcast(END)
-
May 22,2018
- R&D Conference Call (WFH 2018)
-
Products / R&D
- R&D Conference Call (WFH 2018)
- Professor Midori Shima, M.D., Ph.D.
Department of Pediatrics, Nara Medical University
Tatsuro Kosaka, President & CEO, Chugai Pharmaceutical Co., Ltd.
- Presentation [PDF 961KB]
- Webcast(END)
-
Apr 24,2018
- 1Q Results (Jan-Mar 2018) Conference Call
-
Results
Products / R&D
- FY2018 1Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President & CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
- Presentation [PDF 679KB]
- Webcast(END)
-
Apr 12,2018
- Information Meeting on TECENTRIQ®
-
Products / R&D
- 1. TECENTRIQ® Intravenous Infusion 1200mg Product Overview
- Mikio Sakai, TECENTRIQ® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. The Anti-PD-L1 Antibody Tecentriq® Mode of Action and Future Outlook
- Hiroyoshi Nishikawa, M.D., Ph.D.
Department of Immunology, Nagoya University Graduate School of Medicine
Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center - 3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq®
- Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan
- Presentation [PDF 9.6MB]
- Webcast(END)
-
Feb 02,2018
- Investor Conference on FY 2017.12 Financial Results
-
Results
- Aiming to Achieve Mid-Term Business Plan “IBI 18”
-2017 Results and 2018 Outlook- - Tatsuro Kosaka, President, COO
- FY2017 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit
- Presentation [PDF 1.5MB]
- Webcast(END)
- Aiming to Achieve Mid-Term Business Plan “IBI 18”
2017
-
Oct 25,2017
- 3Q Results (Jan - Sep 2017) Conference Call
-
Results
- FY2017 3Q Consolidated Financial Overview
- Toshiaki Itagaki,
Vice President, General Manager of Finance & Accounting Dept. - Overview of Development Pipeline
- Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
- Presentation [PDF 555KB]
- Webcast(END)
-
Jul 28,2017
- Investor Conference on FY2017 2Q Financial Results
-
Results
- FY2017 2Q Consolidated Financial Overview
- Yoshio Itaya,
Executive Vice President, CFO - Overview of Development Pipeline
- Yasushi Ito,
Senior Vice President, Head of Project & Lifecycle Management Unit
- Presentation [PDF 1,016KB]
- Webcast(END)
-
Jul 11,2017
- R&D Conference Call (ISTH 2017)
-
Products / R&D
- R&D Conference Call (ISTH 2017)
- Professor Midori Shima, M.D., PhD.
Department of Pediatrics Nara Medical College
Dr. Hisanori Takanashi, Vice President, General Manager of Clinical Development Div.
- Presentation [PDF 446KB]
- Webcast(END)
-
Jun 29,2017
- R&D Conference Call
-
Products / R&D
- R&D Conference Call
- Megumi Uzu,
Department Manager of Oncology Lifecycle Management Dept.
- Presentation [PDF 1.2MB]
- Webcast(END)
-
Apr 25,2017
- 1Q Results (Jan-Mar 2017) Conference Call
-
Results
- FY2017 1Q Consolidated Financial Overview
- Toshiaki Itagaki,
Vice President, General Manager of Finance & Accounting Dept. - Overview of Development Pipeline
- Shinichiro Iida,
Department Manager of Business Assessment Dept.,
Project & Lifecycle Management Unit
- Presentation [PDF 485KB]
- Webcast(END)
-
Feb 02,2017
- Information Meeting on FY 2016.12 Financial Results
-
Results
- Mid-Term Business Plan “IBI 18”
-2016 Results and 2017 Outlook- - Tatsuro Kosaka, President, COO
- FY2016 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit - Reorganization to Provide a New Solution
- Susumu Kato, Senior Vice President,
General Manager of Marketing & Sales Div.
- Presentation [PDF 896KB]
- Webcast(END)
- Mid-Term Business Plan “IBI 18”
2016
-
Dec 14,2016
- CEO Meeting
-
Corporate
- Challenges Facing Japan’s Pharmaceutical Industry and Orientation of the Solution
- Chairman and CEO Osamu Nagayama
- Presentation [PDF 1.2MB]
- Webcast(END)
-
Oct 25,2016
- 3Q Results (Jan - Sep 2016) Conference Call
-
Results
- FY2016 3Q Consolidated Financial Overview
- Toshiaki Itagaki,
Vice President General Manager of Finance & Accounting Dept. - Overview of Development Pipeline
- Shinichiro Iida,
Department Manager of Business Assessment Dept.,
Project & Lifecycle Management Unit
- Presentation [PDF 457KB]
- Webcast(END)
-
Jul 22,2016
- Information Meeting on FY2016 2Q Financial Results
-
Results
- FY2016 2Q Consolidated Financial Overview
- Yoshio Itaya,
Executive Vice President CFO - Overview of Development Pipeline
- Minoru Watanabe,
Associate Vice President
Deputy General Manager of Research Division
- Presentation [PDF 1.1MB]
- Webcast(END)
-
Jul 04,2016
- R&D Conference Call
-
Products / R&D
- R&D Conference Call
- Megumi Uzu,
Department Manager of Oncology Lifecycle Management Dept.
- Presentation [PDF 618KB]
- Webcast(END)
-
Apr 22,2016
- 1Q Results (Jan-Mar 2016) Conference Call
-
Results
- FY2016 1Q Consolidated Financial Overview
- Toshiaki Itagaki,
Vice President General Manager of Finance & Accounting Dept. - Overview of Development Pipeline
- Minoru Watanabe,
Associate Vice President
Deputy Head of Project & Lifecycle Management Unit
Department Manager of R&D Portfolio Management Dept.
- Presentation [PDF 382KB]
- Webcast(END)
-
Apr 05,2016
- Information Meeting on Bonviva®
-
Products / R&D
- 1. Product Overview of Bonviva® Tablet
- Takeshi Sakaguchi
Bonviva® Product Manager
Chugai Pharmaceutical Co., Ltd. - 2. Bonviva® Tablet: Clinical Utility and Our Expectation
- Hiroshi Hagino, M.D., Ph.D., Professor
School of Health Science
Tottori University Faculty of Medicine, Japan
- Presentation [PDF 3.0MB]
- Webcast(END)
-
Jan 29,2016
- Information Meeting on FY 2015.12 Financial Results
-
Results
- New Mid-Term Business Plan "IBI 18"
- Tatsuro Kosaka, President, COO
- FY2015 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President
- Presentation [PDF 1.8MB]
- Webcast(END)
2015
-
Oct 22,2015
- 3Q Results (Jan 15 - Sep 15) Conference Call
-
Results
- FY2015 3Q Consolidated Financial Overview
- Toshiaki Itagaki,
Vice President General Manager of Finance & Accounting Dept. - Overview of Development Pipeline
- Minoru Watanabe,
Associate Vice President
Deputy Head of Project & Lifecycle Management Unit
Department Manager of R&D Portfolio Management Dept.
- Presentation [PDF 414KB]
- Webcast(END)
-
Jul 24,2015
- Information Meeting on FY 2015.12 2Q Financial Results
-
Results
- FY2015 2Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President
- Presentation [PDF 611KB]
- Webcast(END)
-
Apr 22,2015
- 1Q Results (Jan 15 - Mar 15) Conference Call
-
Results
- FY2015 1Q Consolidated Financial Overview
- Toshiaki Itagaki,
Vice President General Manager of Finance & Accounting Dept. - Overview of Development Pipeline
- Minoru Watanabe,
Associate Vice President
Deputy Head of Project & Lifecycle Management Unit
Department Manager of R&D Portfolio Management Dept.
- Presentation [PDF 333KB]
- Webcast(END)
-
Apr 02,2015
- Information Meeting on ZELBORAF®
-
Products / R&D
- 1. Overview of ZELBORAF®
- Takahiro Mizui
ZELBORAF® Lifecycle Leader
CHUGAI PHARMACEUTICAL CO., LTD. - 2. cobas® BRAF V600 Mutation Test
- Toru Ogawa
Manager, Molecular Diagnostics
Roche Diagnostics K.K. - 3. ZELBORAF® tablet Postmarketing safety measures
- Shin Yoshida
Pharmacovigilance Department
CHUGAI PHARMACEUTICAL CO., LTD. - 4．Overview of melanoma and clinical trials of vemurafenib
- Naoya Yamazaki, M.D., Ph.D.
Chief, Dept. of Dermatologic Oncology
National Cancer Center Hospital, Japan
- Presentation [PDF 2.1MB]
- Webcast(END)
-
Jan 29,2015
- Information Meeting on FY 2014.12 Financial Results
-
Results
- Aiming to Become a Top Pharmaceutical Company
- Tatsuro Kosaka, President, COO
- FY2014 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President,
Head of Project & Lifecycle Management Unit
- Presentation [PDF 746KB]
- Webcast(END)
2014
-
Dec 16,2014
- Information Meeting on Research & Development
-
Products / R&D
- Development Portfolio of Chugai Pharmaceutical
- Yutaka Tanaka, Executive Vice President and Head of Project & Lifecycle Management Unit
- Overview of HER2 Franchise
- Tsuyoshi Takasuka, Oncology Lifecycle Management Dept.
- Overview of Anti-PDL1 Antibody RG7446 (MPDL3280A)
- Mikio Sakai, Oncology Lifecycle Management Dept.
- Overview of Bispecific Antibody ACE910
- Hiroshi Motegi, Primary Lifecycle Management Dept.
- Presentation [PDF 1.2MB]
- Webcast(END)
-
Oct 24,2014
- 3Q Results (Jan 14 - Sep 14) Conference Call
-
Results
- FY2014 3Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President and Head of Project & Lifecycle Management Unit
- Presentation [PDF 475KB]
- Webcast(END)
-
Aug 21,2014
- Information Meeting on ALECENSA®
-
Products / R&D
- Overview of ALECENSA®
- Megumi Uzu,
ALECENSA Lifecycle Leader
Chugai Pharmaceutical Co., Ltd. - Overview of ALK-Rearranged Non-Small Cell Lung Cancer and Clinical Trial of Alectinib (AF-001JP)
- Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan - ALECENSA® Postmarketing Safety Measures
- Chiaki Iiyama,
Pharmacovigilance Dept.
Chugai Pharmaceutical Co., Ltd.
- Presentation [PDF 2.6MB]
- Webcast(END)
-
Jul 25,2014
- Information Meeting on FY 2014.12 2Q Financial Results
-
Results
- FY2014 2Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President Head of Project & Lifecycle Management Unit
- Presentation [PDF 706KB]
- Webcast(END)
-
Apr 24,2014
- 1Q Results (Jan 14 - Mar 14) Conference Call
-
Results
- FY2014 1Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President Head of Project & Lifecycle Management Unit
- Presentation [PDF 440KB]
- Webcast(END)
-
Jan 31,2014
- Information Meeting on FY 2013.12 Financial Results
-
Results
- Aiming to Become a Top Pharmaceutical Company
- Tatsuro Kosaka, President & COO
- FY2013 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President,
Head of Project & Lifecycle Management Unit
- Presentation [PDF 1.6MB]
- Webcast(END)
2013
-
Oct 25,2013
- 3Q Results (Jan 13 - Sep 13) Conference Call
-
Results
- FY2013 3Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President Head of Project & Lifecycle Management Unit
- Presentation [PDF 533KB]
- Webcast(END)
-
Aug 30,2013
- Information Meeting on Bonviva®
-
Products / R&D
- Product Overview of Bonviva®
- Yoshiomi Morishita
Bonviva Product Manager
Chugai Pharmaceutical Co., Ltd. - Clinical Usefulness and Our Expectation of Bonviva®
- Masako Ito, Professor, M.D.
Medical Work-Life-Balance Center
Nagasaki University Hospital, Japan
- Presentation [PDF 3.1MB]
- Webcast(END)
-
Jul 26,2013
- Information Meeting on FY 2013.12 2Q Financial Results
-
Results
- FY2013 2Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President Head of Project & Lifecycle Management Unit
- Presentation [PDF 1.0MB]
- Webcast(END)
-
Apr 25,2013
- 1Q Results (Jan 13 - Mar 13) Conference Call
-
Results
- FY2013 1Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Overview of Development Pipeline
- Hisanori Takanashi, Department Manager, Project Planning & Coordination Dept.
- Presentation [PDF 485KB]
- Webcast(END)
-
Jan 31,2013
- Information Meeting on FY 2012.12 Financial Results
-
Results
- New Mid-Term Business Plan “ACCEL 15”
- Tatsuro Kosaka, President & COO
- FY2012 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President,
Head of Project & Lifecycle Management Unit
- Presentation [PDF 1.8MB]
- Webcast(END)
2012
-
Dec 18,2012
- Information Meeting on Antibody Engineering Technologies
-
Products / R&D
- 1. Proprietary Innovative Antibody Engineering Technologies in Chugai Pharmaceutical
- Hisafumi Okabe, Vice President General Manager of Research Division
- 2. Technology Introduction of SMART-Ig and its Application to Actemra®
- Tomoyuki Igawa, Research Division, Discovery Research Dept.
- 3. Introduction of ART-Ig and application to hemophilia A treatment
- Kunihiro Hattori, Research Division, Department Manager, Discovery Research Dept.
- 4. Technology Introduction of ART-Fc, TRAB, TwoB-Ig, ACT-Ig and its Application
- Hiroyuki Tsunoda, Research Division, Discovery Research Dept.
-
Dec 17,2012
- Financial Reporting Based on IFRS Conference Call
-
Corporate
- Financial Reporting Based on IFRS Conference Call
- Yoshio Itaya, Executive Vice President CFO
- Presentation [PDF 423KB]
- Webcast(END)
-
Nov 16,2012
- Information Meeting on Establishing Stable Cell Lines of Cancer Stem Cell
-
Products / R&D
- Chugai Succeeds in Establishing Stable Cell
Lines of Cancer Stem Cell for the First Time
- A Step Forward in Elucidating the Mechanisms of Recurrence / Metastasis and Drug Resistance of Cancer and in the Development of a New Therapeutic Agent - - Research Division Masami Suzuki
- Chugai Succeeds in Establishing Stable Cell
-
Oct 23,2012
- 3Q Results (Jan 12 - Sep 12) Conference Call
-
Results
- FY2012 3Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Overview of Development Pipeline
- Hisanori Takanashi, Department Manager, R&D Portfolio Management Dept.
-
Jul 27,2012
- Information Meeting on FY 2012.12 2Q Financial Results
-
Results
- FY2012 2Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President,
Head of Project & Lifecycle Management Unit
-
Apr 24,2012
- 1Q Results (Jan 12 - Mar 12) Conference Call
-
Results
- FY2012 1Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President and CFO
- Major Product Update
- Masaaki Tohaya, Senior Vice President, General Manager of Sales Div.
- Overview of Development Pipeline
- Hisanori Takanashi, Department Manager, R&D Portfolio Management Dept.
-
Feb 02,2012
- Information Meeting on FY 2011.12 Financial Results
-
Results
- Aiming to Become a Top Japanese Pharmaceutical Company
- 2011 Results & 2012 Outlook - - Osamu Nagayama, President and CEO
- FY2011 Consolidated Financial Overview
- Yoshio Itaya, Senior Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President,
Head of Lifecycle Management & Marketing Unit
- Aiming to Become a Top Japanese Pharmaceutical Company
2011
-
Oct 28,2011
- Chugai-RDKK PHC Seminar
-
Products / R&D
- 1. Personalized Healthcare (PHC) Approach in Chugai
- Yutaka Tanaka, Senior Vice President, Head of Lifecycle Management & Marketing Unit, CHUGAI PHARMACEUTICAL CO., LTD.
- 2. Role of Clinical Diagnostics for The Personalized Healthcare (PHC)
- Yoshiaki Tazawa, Lifecycle Management of Molecular Diagnostics, Roche Diagnostics K.K.
- 3. R&D Portfolio based on PHC Approach in Chugai
- Hisanori Takanashi, Department Manager, R&D Portfolio Management Dept., CHUGAI PHARMACEUTICAL CO., LTD.
-
Oct 21,2011
- 3Q Results (Jan 11 - Sep 11) Conference Call
-
Results
- FY2011 3Q Consolidated Financial Overview
- Yoshio Itaya, Senior Vice President and CFO
- Overview of Development Pipeline
- Hisanori Takanashi, Department Manager, R&D Portfolio Management Dept.
-
Jul 22,2011
- Information Meeting on FY 2011.12 2Q Financial Results
-
Results
- FY2011 2Q Consolidated Financial Overview
- Yoshio Itaya, Senior Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President,
Head of Lifecycle Management & Marketing Unit
-
Apr 21,2011
- 1Q Results (Jan 11 - Mar 11) Conference Call
-
Results
- FY2011 1Q Consolidated Financial Overview
- Yoshio Itaya, Senior Vice President and CFO
- Overview of Development Pipeline
- Hisanori Takanashi, Department Manager, R&D Portfolio Management Dept.
-
Feb 03,2011
- Information Meeting on FY 2010.12 Financial Results
-
Results
- Aiming to Become a Top Japanese Pharmaceutical Company
- Review of 2010 and Plans for 2011 - - Osamu Nagayama, President and CEO
- FY2010 Consolidated Financial Overview
- Yoshio Itaya, Senior Vice President and CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Senior Vice President,
Head of Lifecycle Management & Marketing Unit
- Aiming to Become a Top Japanese Pharmaceutical Company
2010
-
Oct 22,2010
- 3Q Results (Jan 10 - Sep 10) Conference Call
-
Results
- FY2010 3Q Consolidated Financial Overview
- Executive Vice President and CFO, Ryuzo Kodama
- Overview of Development Pipeline
- Senior Vice President, Head of Portfolio Management Unit, Yutaka Tanaka
-
Oct 08,2010
- Information Meeting
-
Corporate
- Roche: adapting to the changing environment
- Severin Schwan, CEO, Roche Group
- Aiming to Become a Top Japanese Pharmaceutical Company - Advancing into the Next Stage -
- Osamu Nagayama, President and CEO, Chugai Pharmaceutical Co., Ltd.
-
Sep 29,2010
- Deutsche Bank Conference
-
Conference
- Deutsche Bank Conference
- Ryuzo Kodama, Executive Vice President and CFO
-
Sep 08,2010
- Information Meeting on Actemra
-
Products / R&D
- Actemra Product Overview
- Katsunori Yoshizawa, Actemra Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- Removal of Conditions on Approval of Actemra for Intravenous Infusion with All Patients Surveillance
- Shunji Yokoyama, Pharmacovigilance Manager, Chugai Pharmaceutical Co., Ltd.
- Actemra Results of All Patients Surveillance and Its Position in RA Treatment in Japan
- Tsutomu Takeuchi, M.D. Ph.D., Division of Rheumatology, School of Medicine, Keio University
-
Jul 23,2010
- Information Meeting on FY 2010.12 2Q Financial Results
-
Results
- Aiming to Become a Top Japanese Pharmaceutical Company
Review of Half Year 2010 - Osamu Nagayama, President and CEO
- FY2010 2Q Consolidated Financial Overview
- Ryuzo Kodama, Executive Vice President and CFO
- Overview of Development Pipeline
- Tatsuro Kosaka, Executive Vice President,
Head of Lifecycle Management Marketing Unit.
- Aiming to Become a Top Japanese Pharmaceutical Company
-
Apr 23,2010
- 1Q Results (Jan 10 - Mar 10) Conference Call
-
Results
- FY2010 1Q Consolidated Financial Overview
- Yoshio Itaya, Senior Vice President,
General Manager of Finance Supervisory Div. and General Manager of Finance & Accounting Dept. - Overview of R&D Activities
- Hisanori Takanashi, Department Manager,
Project Management Dept.
-
Feb 04,2010
- Information Meeting on FY 2009.12 Financial Results
-
Results
- Aiming to Become a Top Japanese Pharmaceutical Company
- Review of 2009 and Plans for 2010 - - Osamu Nagayama, President and CEO
- FY2009 Consolidated Financial Overview
- Ryuzo Kodama, Executive Vice President and CFO
- Overview of R&D Activities
- Yutaka Tanaka, Senior Vice President,
Head of Portfolio Management Unit
- Aiming to Become a Top Japanese Pharmaceutical Company
2009
-
Dec 07,2009
- Information Meeting on Diabetes Products
-
Products / R&D
- Overview of Chugai Diabetes
- Hisanori Takanashi, Department Manager, Project Management Dept.
- Overview of taspoglutide
- Takaki Koga, Project Management Dept.
- Overview of CSG452
- Sachiya Ikeda, Project Management Dept.
-
Dec 01,2009
- Nomura Investment Forum 2009
-
Conference
- Nomura Investment Forum 2009
- Osamu Nagayama, President and CEO
-
Oct 27,2009
- 3Q Results (Jan 09 - Sep 09) Conference Call
-
Results
- FY2009 3Q Consolidated Financial Overview
- Toshiaki Itagaki, General Manager, Finance & Accounting Dept.
- Overview of Development Pipeline
- Hisanori Takanashi, Department Manager, Project Management Dept.
-
Sep 30,2009
- Deutsche Bank Conference
-
Conference
- Deutsche Bank Conference
- Osamu Nagayama, President and CEO
-
Aug 26,2009
- Tour of Utsunomiya Plant
-
Products / R&D
- Observation on Follow-on Biologics / Biosimilars
- Group Manager, External Affairs Dept.
Junichi Matsuzaki, Ph. D.
-
Jul 24,2009
- Information Meeting on FY 2009.12 2Q Financial Results
-
Results
- 1)FY2009 2Q Consolidated Financial Overview
- Ryuzo Kodama, Executive Vice President and CFO
- 2)Overview of Development Pipeline
- Tatsuro Kosaka, Senior Vice President,
Head of Lifecycle Management Marketing Unit.
-
Apr 24,2009
- 1Q Results (Jan 09 - Mar 09) Conference Call
-
Results
- FY2009 1Q Consolidated Financial Overview
- Toshiaki Itagaki, General Manager, Finance & Accounting Dept.
- Overview of R&D Activities
- Hisanori Takanashi, Department Manager, Project Management Dept.
-
Mar 27,2009
- Information Meeting
-
Corporate
- 1)Aiming to Become a Top Japanese Pharmaceutical Company with Global-Level Capabilities
- Osamu Nagayama, President and CEO
-
Feb 05,2009
- Information Meeting on FY 2008.12 Financial Results
-
Results
- 1)FY2008 Consolidated Financial Overview
- Ryuzo Kodama, Executive Vice President and CFO
- 2)Overview of Development Pipeline
- Tatsuro Kosaka, Senior Vice President,
Head of Lifecycle Management Marketing Unit.
2008
-
Oct 21,2008
- 3Q Results (Jan 08 - Sep 08) Conference Call
-
Results
- FY2008 3Q Consolidated Financial Overview
- Toshiaki Itagaki, General Manager, Finance & Accounting Dept.
- Overview of R&D Activities
- Yutaka Tanaka, Vice President, General Manager of Clinical Development Div.
-
Sep 02,2008
- Media Conference on Avastin
-
Products / R&D
- 1)Overview of Avastin and Assessment of its Proper Use in Japan
- Kosuke Iijima,
Avastin Product Manager - 2)Progress in the Treatment of Metastatic Colorectal Cancer
One Year After the Launch of Avastin - Yasuhide Yamada,
Gastrointestinal Oncology Division,
National Cancer Center Hospital, Japan
-
Aug 01,2008
- Information Meeting on 2008.12 Half-Year Financial Results
-
Results
- 1)FY2008 Interim Consolidated Financial Overview
- Ryuzo Kodama, Executive Vice President & CFO
- 2)Overview of R&D Activities
- Tatsuro Kosaka, Senior Vice President
Head of Lifecycle Management Marketing Unit
-
May 22,2008
- Information Meeting on Actemra
-
Products / R&D
- 1)Product Overview of Actemra
- Tadao Shimizu,
Actemra Product Manager
Chugai Pharmaceutical Co., Ltd. - 2)Treatment evolution
- from "alleviating & delaying" to "stopping" disease progression - - Tsutomu Takeuchi, MD. PhD.
Vice Dean of Saitama Medical School
Professor of Medicine, Division of Rheumatology, Clinical Immunology Saitama Medical Center, Saitama Medical University
-
Apr 22,2008
- 1Q Results (Jan 08 - Mar 08) Conference Call
-
Results
- FY2008 1Q Consolidated Financial Overview
- Ryuzo Kodama, Executive Vice President and CFO
- Overview of R&D Activities
- Mikio Arisawa, Senior Vice President, Research, Head of Portfolio Management Unit
-
Mar 03,2008
- Media Conference on Herceptin
-
Products / R&D
- 1)Herceptin
- Takahiro Yamaguchi,
Oncology Unit, Breast Cancer Group, Herceptin Product Manager
Chugai Pharmaceutical Co., Ltd. - 2)Adjuvant Therapy with Trastuzumab
- Hiroji Iwata, M.D.
Department of Breast Oncology, Aichi Cancer Center Hospital - 3)Pharmacoeconomics of Trastuzumab (Herceptin)
- Takashi Fukuda, Ph.D.
Department of Health Economics and Epidemiology Research
Graduate School of Medicine, The University of Tokyo
-
Jan 31,2008
- Information Meeting on FY 2007.12 Financial Results
-
Results
- 1)New Mid-Term Business Plan "Sunrise 2012"
- Osamu Nagayama, President and CEO
- 2)FY2007 Consolidated Financial Overview
- Ryuzo Kodama, Executive Vice President and CFO
- 3)Overview of R&D Activities
- Tatsuro Kosaka, Senior Vice President,
Head of Strategic Marketing Unit and General Manager of Strategic Planning Dept.
